Table 4 Antibody-dependent cellular cytotoxicity results in six USPC cell lines

From: In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma

Sample

Control (%)

Rituximab (%)

Trastuzumab (%) a

Pertuzumab (%) a

Combination (%) b

USPC ARK-1

1.6

4.5

44.7

52.8

54.2

USPC ARK-2

0.7

0.5

63.8

62

58.1

USPC ARK-3

0.6

1.9

67.3

66.7

68.8

USPC ARK-4

0.2

0.4

14.1

2.2

26.1

USPC ARK-5

4.7

3.7

34.5

17.7

41.1

USPC ARK-6

4.6

4.5

56.2

25.3

65.7

  1. Abbreviation: USPC=uterine serous papillary adenocarcinoma.
  2. a Dose of pertuzumab and trastuzumab was 2.5 μg ml−1.
  3. b Pertuzumab 1.25 μg ml−1 and trastuzumab 1.25 μg ml−1. The combination of pertuzumab and trastuzumab was significantly more effective in inducing antibody-dependent cell-mediated cytotoxicity in all three USPC cell lines that express low levels of HER2/neu when compared with the use of pertuzumab or trastuzumab used alone (Kruskal–Wallis test and χ2 analysis; P=0.001).
  4. Results from a representative cytotoxicity experiment for each cell lines are shown.
Back to article page